Relmada Therapeutics RLMD
NASDAQ RLMD
$3.21 -0.15 (-4.46%)
At close: Oct 21, 2026 · 4:00 PM EDT

Relmada Therapeutics (RLMD) EBT Margin (2012 - 2023)

Updated

Relmada Therapeutics' EBT Margin came in at -877.66% for FY2013, down 725.89 percentage points from -151.77% in FY2012.

Analysis

Relmada Therapeutics (RLMD) EBT Margin (2012 - 2023) Analysis & Trends

  • Per Business Quant, earlier years put EBT Margin at -151.77% in FY2012.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Margin (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 40.25%
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 26.66%
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 25.18%
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn -4.11%
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn 29.63%
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 18.19%
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 27.53%
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn -131.41%
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn -4.34%
10 Relmada Therapeutics 361.29 Mn -197.30 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2023 -2,030.62%
Sep 30, 2023 -1,617.26%
Jun 30, 2023 -1,808.95%
Mar 31, 2023 -4,981.48%
Dec 31, 2022 -3,579.66%
Sep 30, 2022 -14,564.87%
Jun 30, 2022 -11,051.05%
Mar 31, 2022 -12,160.73%
Dec 31, 2021 -95,047.20%
Dec 31, 2020 -9,329.66%
Sep 30, 2020 -4,629.86%
Sep 30, 2019 -9,677.96%
Mar 31, 2019 -16,952.16%
Sep 30, 2017 -177.52%
Jun 30, 2017 -865,477.67%
Mar 31, 2017 -482,653.70%
Jun 30, 2016 -163,632.54%
Mar 31, 2016 -353,096.14%
Jun 30, 2015 -910,343.02%
Mar 31, 2015 -198,697.52%
API Access

Relmada Therapeutics EBT Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebt-margin&ticker=RLMD&period=max&api_key=YOUR_API_KEY